Understanding how a protein called SNED1 affects tissue structure and cancer progression
Mechanisms guiding the fibrillar assembly of SNED1 in the extracellular matrix
This study is looking at a protein called SNED1 to see how it helps build the support structure of tissues and affects breast cancer, with the hope of finding new ways to improve treatment and outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-10899600 on NIH RePORTER |
What this research studies
This research investigates the role of a protein known as SNED1 in the extracellular matrix (ECM), which is crucial for the structural integrity of tissues and the regulation of cellular functions. By studying how SNED1 contributes to the assembly of the ECM and its impact on breast cancer, the researchers aim to uncover mechanisms that could lead to better understanding and treatment of aggressive cancers. The study utilizes advanced genetic models to explore the effects of SNED1 on cell behavior and disease outcomes, particularly in breast cancer patients. Insights gained from this research could help identify new therapeutic targets for improving patient prognosis.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with aggressive forms of breast cancer, particularly those showing high levels of SNED1 expression.
Not a fit: Patients with non-aggressive breast cancer or other types of cancer unrelated to ECM alterations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with aggressive breast cancer by targeting the mechanisms involving SNED1.
How similar studies have performed: While research on ECM proteins is ongoing, the specific focus on SNED1 and its implications in breast cancer is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Naba, Alexandra — University of Illinois at Chicago
- Study coordinator: Naba, Alexandra
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.